Antipsychotic drugs and QTc prolongation: The potential role of CYP2D6 genetic polymorphism

Pedro Dorado, Roland Berecz, Eva M. Peñas-LLedó, Adrián LLerena

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Although the most common, and usually serious, side effects of first-generation (or typical) antipsychotic drugs, such as Parkinsonism, dystonias and tardive dyskinesia, were known from early times, their cardiovascular safety was not properly in the focus of treatment management. The growing evidence of these drug-related cardiac changes and the appearance of potentially fatal dysrhythmias have increased the interest on their safety profile. Thus, the introduction of the new second-generation (atypical) antipsychotic drugs put emphasis on the preregistration evaluation of the potential cardiac side effects and electrocardiogram predictors (QT interval lengthening). In spite of this, these drugs do not appear to be exempt from these potential risks. The present review summarizes up-to-date knowledge about the cardiac safety of antipsychotic drugs, and analyses the role of drug metabolic processes (CYP2D6 genetic polymorphism) in the complex pathophysiology of the phenomenon. In addition, some recommendations are formulated.

Original languageEnglish
Pages (from-to)9-19
Number of pages11
JournalExpert Opinion on Drug Metabolism and Toxicology
Volume3
Issue number1
DOIs
Publication statusPublished - Feb 2007

Fingerprint

Cytochrome P-450 CYP2D6
Genetic Polymorphisms
Polymorphism
Antipsychotic Agents
Safety
Pharmaceutical Preparations
Cohort Effect
Dystonia
Bioelectric potentials
Parkinsonian Disorders
Electrocardiography

Keywords

  • Antipsychotic drugs
  • Cardiac side effects
  • CYP2D6
  • Drug metabolism
  • QT interval lengthening
  • Torsades de pointes-type arrhythmia

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Cite this

Antipsychotic drugs and QTc prolongation : The potential role of CYP2D6 genetic polymorphism. / Dorado, Pedro; Berecz, Roland; Peñas-LLedó, Eva M.; LLerena, Adrián.

In: Expert Opinion on Drug Metabolism and Toxicology, Vol. 3, No. 1, 02.2007, p. 9-19.

Research output: Contribution to journalArticle

@article{e02ddaa0007d443cbff28d72953336f2,
title = "Antipsychotic drugs and QTc prolongation: The potential role of CYP2D6 genetic polymorphism",
abstract = "Although the most common, and usually serious, side effects of first-generation (or typical) antipsychotic drugs, such as Parkinsonism, dystonias and tardive dyskinesia, were known from early times, their cardiovascular safety was not properly in the focus of treatment management. The growing evidence of these drug-related cardiac changes and the appearance of potentially fatal dysrhythmias have increased the interest on their safety profile. Thus, the introduction of the new second-generation (atypical) antipsychotic drugs put emphasis on the preregistration evaluation of the potential cardiac side effects and electrocardiogram predictors (QT interval lengthening). In spite of this, these drugs do not appear to be exempt from these potential risks. The present review summarizes up-to-date knowledge about the cardiac safety of antipsychotic drugs, and analyses the role of drug metabolic processes (CYP2D6 genetic polymorphism) in the complex pathophysiology of the phenomenon. In addition, some recommendations are formulated.",
keywords = "Antipsychotic drugs, Cardiac side effects, CYP2D6, Drug metabolism, QT interval lengthening, Torsades de pointes-type arrhythmia",
author = "Pedro Dorado and Roland Berecz and Pe{\~n}as-LLed{\'o}, {Eva M.} and Adri{\'a}n LLerena",
year = "2007",
month = "2",
doi = "10.1517/17425255.3.1.9",
language = "English",
volume = "3",
pages = "9--19",
journal = "Expert Opinion on Drug Metabolism and Toxicology",
issn = "1742-5255",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Antipsychotic drugs and QTc prolongation

T2 - The potential role of CYP2D6 genetic polymorphism

AU - Dorado, Pedro

AU - Berecz, Roland

AU - Peñas-LLedó, Eva M.

AU - LLerena, Adrián

PY - 2007/2

Y1 - 2007/2

N2 - Although the most common, and usually serious, side effects of first-generation (or typical) antipsychotic drugs, such as Parkinsonism, dystonias and tardive dyskinesia, were known from early times, their cardiovascular safety was not properly in the focus of treatment management. The growing evidence of these drug-related cardiac changes and the appearance of potentially fatal dysrhythmias have increased the interest on their safety profile. Thus, the introduction of the new second-generation (atypical) antipsychotic drugs put emphasis on the preregistration evaluation of the potential cardiac side effects and electrocardiogram predictors (QT interval lengthening). In spite of this, these drugs do not appear to be exempt from these potential risks. The present review summarizes up-to-date knowledge about the cardiac safety of antipsychotic drugs, and analyses the role of drug metabolic processes (CYP2D6 genetic polymorphism) in the complex pathophysiology of the phenomenon. In addition, some recommendations are formulated.

AB - Although the most common, and usually serious, side effects of first-generation (or typical) antipsychotic drugs, such as Parkinsonism, dystonias and tardive dyskinesia, were known from early times, their cardiovascular safety was not properly in the focus of treatment management. The growing evidence of these drug-related cardiac changes and the appearance of potentially fatal dysrhythmias have increased the interest on their safety profile. Thus, the introduction of the new second-generation (atypical) antipsychotic drugs put emphasis on the preregistration evaluation of the potential cardiac side effects and electrocardiogram predictors (QT interval lengthening). In spite of this, these drugs do not appear to be exempt from these potential risks. The present review summarizes up-to-date knowledge about the cardiac safety of antipsychotic drugs, and analyses the role of drug metabolic processes (CYP2D6 genetic polymorphism) in the complex pathophysiology of the phenomenon. In addition, some recommendations are formulated.

KW - Antipsychotic drugs

KW - Cardiac side effects

KW - CYP2D6

KW - Drug metabolism

KW - QT interval lengthening

KW - Torsades de pointes-type arrhythmia

UR - http://www.scopus.com/inward/record.url?scp=34250354021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250354021&partnerID=8YFLogxK

U2 - 10.1517/17425255.3.1.9

DO - 10.1517/17425255.3.1.9

M3 - Article

C2 - 17269891

AN - SCOPUS:34250354021

VL - 3

SP - 9

EP - 19

JO - Expert Opinion on Drug Metabolism and Toxicology

JF - Expert Opinion on Drug Metabolism and Toxicology

SN - 1742-5255

IS - 1

ER -